|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MFSD4 |
Gene summary for MFSD4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MFSD4 | Gene ID | 148808 |
| Gene name | major facilitator superfamily domain containing 4A | |
| Gene Alias | MFSD4 | |
| Cytomap | 1q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q8N468 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 148808 | MFSD4 | P1T-E | Human | Esophagus | ESCC | 5.20e-08 | 6.14e-01 | 0.0875 |
| 148808 | MFSD4 | P8T-E | Human | Esophagus | ESCC | 5.30e-21 | 3.86e-01 | 0.0889 |
| 148808 | MFSD4 | P10T-E | Human | Esophagus | ESCC | 9.24e-88 | 1.57e+00 | 0.116 |
| 148808 | MFSD4 | P12T-E | Human | Esophagus | ESCC | 9.35e-10 | 2.35e-01 | 0.1122 |
| 148808 | MFSD4 | P23T-E | Human | Esophagus | ESCC | 2.24e-15 | 8.20e-01 | 0.108 |
| 148808 | MFSD4 | P26T-E | Human | Esophagus | ESCC | 1.96e-05 | 1.16e-01 | 0.1276 |
| 148808 | MFSD4 | P27T-E | Human | Esophagus | ESCC | 1.96e-05 | 1.26e-01 | 0.1055 |
| 148808 | MFSD4 | P31T-E | Human | Esophagus | ESCC | 3.19e-23 | 5.76e-01 | 0.1251 |
| 148808 | MFSD4 | P39T-E | Human | Esophagus | ESCC | 1.66e-02 | 1.33e-01 | 0.0894 |
| 148808 | MFSD4 | P54T-E | Human | Esophagus | ESCC | 9.07e-08 | 1.91e-01 | 0.0975 |
| 148808 | MFSD4 | P57T-E | Human | Esophagus | ESCC | 1.96e-05 | 1.64e-01 | 0.0926 |
| 148808 | MFSD4 | P61T-E | Human | Esophagus | ESCC | 6.66e-17 | 3.72e-01 | 0.099 |
| 148808 | MFSD4 | P62T-E | Human | Esophagus | ESCC | 4.33e-10 | 3.82e-01 | 0.1302 |
| 148808 | MFSD4 | P65T-E | Human | Esophagus | ESCC | 1.12e-10 | 2.32e-01 | 0.0978 |
| 148808 | MFSD4 | P74T-E | Human | Esophagus | ESCC | 1.86e-07 | 3.66e-01 | 0.1479 |
| 148808 | MFSD4 | P75T-E | Human | Esophagus | ESCC | 3.60e-13 | 3.69e-01 | 0.1125 |
| 148808 | MFSD4 | P82T-E | Human | Esophagus | ESCC | 8.01e-19 | 1.07e+00 | 0.1072 |
| 148808 | MFSD4 | P84T-E | Human | Esophagus | ESCC | 1.34e-04 | 2.67e-01 | 0.0933 |
| 148808 | MFSD4 | P127T-E | Human | Esophagus | ESCC | 2.67e-14 | 2.85e-01 | 0.0826 |
| 148808 | MFSD4 | P128T-E | Human | Esophagus | ESCC | 3.30e-05 | 2.69e-01 | 0.1241 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008643 | Liver | HCC | carbohydrate transport | 80/7958 | 152/18723 | 7.34e-03 | 2.92e-02 | 80 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |